Fresenius Medical Care files 2025 Form 20-F
Fresenius Medical Care, a leading global provider of dialysis products and services, has filed its Annual Report on Form 20-F for fiscal year 2025 with the U.S. Securities and Exchange Commission.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Fresenius Medical Care, a leading global provider of dialysis products and services, has filed its Annual Report on Form 20-F for fiscal year 2025 with the U.S. Securities and Exchange Commission. The full report, including audited consolidated financial statements, is available on the company’s website and from the SEC.
The company treats individuals with renal diseases through a network of 3,601 dialysis clinics serving approximately 292,000 patients and supports around 4.5 million people worldwide who regularly undergo dialysis. Printed copies of the 20-F can be requested free of charge from the investor relations department.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Fresenius Medical Care (FMS) announce in this Form 6-K filing?
Where can investors access Fresenius Medical Care’s 2025 Form 20-F?
How can I request a hard copy of Fresenius Medical Care’s 20-F report?
What business does Fresenius Medical Care (FMS) operate according to this filing?
On which stock exchanges is Fresenius Medical Care listed?
Does this Fresenius Medical Care filing include forward-looking statements?
AI-generated analysis. How Rhea-AI works. Not financial advice.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934
For the month of February 2026
Commission file number: 001-32749
FRESENIUS MEDICAL CARE AG
(Translation of registrant's name into English)
Else-Kröner Strasse 1
61346 Bad Homburg
Germany
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
EXHIBITS
The following exhibits are being furnished with this Report:
| Exhibit 99.1 | Press Release issued on February 24, 2026. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
DATE: February 24, 2026
| Fresenius Medical Care AG | ||
| By: | /s/ Helen Giza | |
| Name: | Helen Giza | |
| Title: | Chief Executive Officer and Chair of the Management Board | |
| By: | /s/ Martin Fischer | |
| Name: | Martin Fischer | |
| Title: | Chief Financial Officer and member of the Management Board | |
Exhibit 99.1
| Press Release | Media contact Christine Peters T +49 160 60 66 770 christine.peters@freseniusmedicalcare.com
Contact for analysts and investors Dr. Dominik Heger T +49 6172 609 2601 dominik.heger@freseniusmedicalcare.com
www.freseniusmedicalcare.com |
Fresenius Medical Care published Report on Form 20-F for fiscal year 2025
Bad Homburg (February 24, 2026) – Fresenius Medical Care (FME), the world’s leading provider of products and services for individuals with renal diseases, has filed the Annual Report 2025 on Form 20-F with the U.S. Securities and Exchange Commission (SEC). The report is available at FME’s website (www.freseniusmedicalcare.com) in the “Investors” section as well as on the SEC’s website (www.sec.gov).
A hard copy of FME’s Annual Report on Form 20-F, including the complete audited consolidated financial statements, may be obtained from the Company free of charge upon request to FME’s Investor Relations department by email at ir@freseniusmedicalcare.com.
About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.5 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,601 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 292,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the Company’s website at www.freseniusmedicalcare.com.
Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various risk factors and uncertainties, including, but not limited to, changes in business, economic or competitive conditions, changes in reimbursement, regulatory compliance issues, regulatory reforms, results of clinical studies, foreign exchange rate and interest rate fluctuations, uncertainties in litigation or investigative proceedings, cyber security issues and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care’s reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release.
Page 1/1